BioCryst Pharmaceuticals, Inc.

Today we announced the appointment of Sandeep Menon, MD, PhD, as Chief Research and Development Officer. Dr. Menon joins BioCryst as an experienced R&D leader with a track record of advancing innovative therapies from early development to global approval. bit.ly/4cs3t5P

We’re looking forward to connecting with the #HAE community and those in the allergy and immunology field in at #AAAAI26. bit.ly/4al9Eqc @AAAAI_org

We are excited to announce that John Ruesch has joined BioCryst as Chief Technical Operations Officer. bit.ly/49EGZ0h

Happening now: BioCryst is presenting at #JPM2026. Access the webcast here: (bit.ly/3C9gv96) #JPMHC26

We’re excited to come together with the healthcare industry today at the 44th Annual @jpmorgan Healthcare Conference, where we will present our latest updates and business outlook for the year. Learn more: bit.ly/3LHLNbQ #JPM2026 #JPMHC26 #JPM26

The FDA approval of our prophylactic therapy for children aged 2 to <12 with hereditary angioedema marks a transformative moment for families who live with HAE and the physicians who treat the condition. bit.ly/48KnvW9

We are proud to announce that the US FDA approved our prophylactic therapy for the treatment of hereditary angioedema (HAE) in children aged 2 to <12 years. bit.ly/48KnvW9

Today we announced the presentation of new data at the @ACAAI 2025 Annual Scientific Meeting. Stop by our poster sessions to learn more. #ACAAI25 bit.ly/3LqZQlJ

We’re looking forward to connecting with the #HAE community and those in the allergy and immunology field at the @ACAAI 2025 Annual Scientific Meeting bit.ly/4o8NQnr #ACAAI25

Today we announced that we will acquire Astria Therapeutics. Read more: bit.ly/3J8WrHg

Today we announced that Charlie Gayer will succeed Jon Stonehouse as Chief Executive Officer upon his retirement in December. bit.ly/4ocl7hM

We are excited to be attending the 2025 @US_HAEA National Summit in Baltimore and looking forward to connecting with the #HAE community. bit.ly/44mCTY2

We are excited to announce that Babar Ghias joins BioCryst as our new Chief Financial Officer and Head of Corporate Development. bit.ly/4l9GNt7

Today we announced the sale of our European business to Neopharmed Gentili. Read more: bit.ly/44xFE8N

We presented new data at the European Academy of Allergy and Clinical Immunology (@EAACI_HQ) Congress 2025: bit.ly/3TegtSt #EAACI2025

We are looking forward to connecting with the #HAE community and presenting new data at the European Academy of Allergy and Clinical Immunology (@EAACI_HQ) Congress 2025: bit.ly/3T1zEOW #EAACI2025

Today we announced the presentation of new data at the C1-Inhibitor Deficiency & Angioedema Workshop in Budapest. bit.ly/3ZDd7f8

We presented at the @ISPORorg Patient-Centered Research Summit 2025 this week, sharing real-world evidence. bit.ly/42YkuQy

We're pleased to announce the FDA acceptance of our New Drug Application for our oral prophylactic therapy for patients with hereditary angioedema (#HAE) aged 2 to 11 years. bit.ly/3ZcSdmU

Today we announced the appointment of healthcare investment banking leader, Steve Frank, to our board of directors. Read more: bit.ly/3ENYMFt